Corix Bioscience (Corix Bioscience) Sloan Ratio % : -157.92% (As of Sep. 2017)

Corix Bioscience Sloan Ratio % Chart

Corix Bioscience Quarterly Data
	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Sloan Ratio %	Get a 7-Day Free Trial															-	-23.31	-	-28.97	-157.92

Competitive Comparison of Corix Bioscience's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's Sloan Ratio % falls into.

Corix Bioscience Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Corix Bioscience's Sloan Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Corix Bioscience's Sloan Ratio for the quarter that ended in Sep. 2017 is calculated as

Corix Bioscience's Net Income for the trailing twelve months (TTM) ended in Sep. 2017 was -0.139 (Dec. 2016 ) + -0.204 (Mar. 2017 ) + -2.158 (Jun. 2017 ) + -3.14 (Sep. 2017 ) = $-5.64 Mil.
Corix Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2017 was -0.348 (Dec. 2016 ) + -0.268 (Mar. 2017 ) + -0.794 (Jun. 2017 ) + -1.722 (Sep. 2017 ) = $-3.13 Mil.
Corix Bioscience's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2017 was -0.114 (Dec. 2016 ) + 0.381 (Mar. 2017 ) + 0.699 (Jun. 2017 ) + 3.385 (Sep. 2017 ) = $4.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience  (GREY:CXBS) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2017, Corix Bioscience has a Sloan Ratio of -157.92%, indicating there is a warning stage of accrual build up.

Corix Bioscience Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Corix Bioscience's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Corix Bioscience (Corix Bioscience) Business Description